Exc Share Discussion Threads

[0verzeal] 02/10/2009 16:32

This is the email reply.

Further to your query left on the website, we've been discussing all the options, including PLUS and Rivington Street (for matched bargains), and hope to finalise our proposals in the next two weeks.

Disposal of shares, is, of course, a major concern and we'll certainly try to resolve it as best we can.

Michael Edelson

[knowing] 02/10/2009 08:08

What they delisting?

[topinfo] 01/10/2009 15:06

PYC next EXC


Just out

Physiomics Trading Statement



TIDMPYC

RNS Number : 0816A
Physiomics PLC
01 October 2009

?
Trading Update


Physiomics plc ("Physiomics" or "the Company")


Highlights:


* Revenue for year ended 30 June 2009 is expected to exceed the forecast of
GBP440k made in July 2008
* Good progress on Lilly collaboration, with license agreement signed in April
2009
* Achievement of second year milestone on Tempo project
* Looking to leverage Physiomics' technology for non-pharmaceutical application



Trading Update


Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is
pleased to update the market on its trading performance for the financial year
ended 30 June 2009. Revenues for the year were stronger than anticipated in a
previous trading statement issued on 28 July 2008 and we were able to build on
the improvement set out in the Interim statement issued in February 2009.


Conversion of debt into equity announced in August 2009 totalling GBP24k has
also helped to reduce the deficit in equity shareholders' funds which stood at
GBP102k at 31 December 2008.


Since the publication of its interim results for the period ended 31 December
2008, Physiomics has made good progress with its collaboration with Eli Lilly
and Company ("Lilly"), and in particular has announced on 2 April 2009 a license
agreement with Lilly for a customised version of its "ModelPlayer(TM)" for in
silico simulations of unspecified anticancer drugs. These are project specific
licences.


The Company is in discussion with a number of major players in the oncology
sector and expects to be able to say more in the near future.


Furthermore, Physiomics has announced on 23 June 2009 a successful
evaluation, by the European Commission, of the results from the second year of
the research program "TEMPO". This is the most important phase of the project
and Physiomics' partners will start imminently to verify in an in vivo
pre-clinical model the optimal chronotherapeutic schedules produced by
Physiomics. When validated, this will served as a base for a further grant
application, with the aim to test these chronotherapeutic schedules in a clinic
setting.


If the TEMPO approach is validated then it has both the potential to evaluate
existing oncology compounds to see whether a more efficient dosing regimen is
possible as well as helping formulate optimal study protocols for drugs used in
combination therapy. This would provide data on the ideal dosing sequence, time
interval between doses and amounts to be dosed.


The biological models are supported by sophisticated simulation software
environments developed by the team these include the Model Player(TM) and a
version of the proprietary SystemCell technology running on the IBM "Blue C"
super computer at the Institute of Life Sciences at Swansea University. We
intend to leverage this technology platform for non-pharmaceutical application
and we are looking at diversification in other areas and in particular Synthetic
Biology.


Commenting on the trading update, Physiomics' Chief Operating Officer, Dr
Christophe Chassagnole, said: "We are really pleased to have exceeded our
revenue forecast for the last year thanks to the good progress in our
collaborations. Based on these achievements plus the recent technical
development in the area of combination and scheduling and the potential to
branch out into wholly new applications, we are confident that we can stimulate
even greater interest in our technology."




For further information:


Physiomics plc
Dr Christophe Chassagnole, COO
[phone]


WH Ireland Limited
Katy Mitchell
[phone]

[knowing] 01/10/2009 13:54

Thing is with EXC that the market has always kept a flat book on the stock.

[0verzeal] 01/10/2009 13:00

double6,
370 million shares.
Net assets around £1 million.

So yes !

[double6] 01/10/2009 12:54

Did I see a fall of 0.05p in your Net Asset figure there, OZ, or was I seeing things ??!!

[0verzeal] 01/10/2009 12:44

Net assets are 0.3p !

[knowing] 01/10/2009 12:39

More bloody activity then when it was a going concern

LOL

[0verzeal] 01/10/2009 12:38

Selected purchases on PLUS !

12:09:16 0.25p 1,000,000 £2,490.00
11:40:04 0.25p 120,000 £300.00
11:10:16 0.25p 181,369 £453.42
11:02:08 0.25p 75,640 £189.10
10:44:17 0.35p 55,041 £192.09

[0verzeal] 01/10/2009 12:35

A million purchased at 0.25p on PLUS just gone through !

[garykc] 01/10/2009 12:23

Just sold my holdings in ZEST as was doing nothing. You watch these rocket now LOL. Bought into GKP though at 71p.

[r3covery] 01/10/2009 12:21

picked up 250k in zest.

[r3covery] 01/10/2009 12:08

gl has anyone looked at zest for a punt. looking at buying a tiddle.

[0verzeal] 01/10/2009 11:59

I have emailed them.

[r3covery] 01/10/2009 11:47

normally they mention listing elsewhere. no mention in interims. unless you have spoken to management.

[knowing] 01/10/2009 11:39

It's possible to saw no mention.

[0verzeal] 01/10/2009 11:31

Can EXC continue and be traded on Plus ?
Thanks in anticipation.

[0verzeal] 01/10/2009 11:15

Large shareholders will not want to delist.
They'll stump up the necessary money.
Dilution though.
IMO

[r3covery] 01/10/2009 11:05

was looking to buy a few. read the interims. delisting is the end.

[r3covery] 01/10/2009 11:01

these are delisting.

[wiganer] 30/9/2009 16:48

Elliot Richard Fidler - Finance Director

Classic